Biosimilars Are Here. Now What? | The Financialist
The market for biologics, which are often produced by genetically modified cells and act like naturally occurring substances, has grown fast and is still expanding. Biologics accounted for 29 percent ($159 billion) of global pharmaceutical sales (not including generics) in 2014, up from 10 percent in 2000, and are expected to reach a full 30 percent ($181 billion) by 2016, according to Credit Suisse’s biotech analysts. It’s the moment biosimilars have been waiting for, as the first generation of branded biologics is starting to lose exclusivity. -
See more at: https://www.thefinancialist.com/biosimilars-are-here-now-what/?utm_source=taboola&utm_term=bloomberg&utm_campaign=Global#sthash.GvBuR3it.dpuf
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment